Christian Boehringer to hand over as Chairman of the Shareholders’ Committee to Hubertus von Baumbach Shashank Deshpande, Member of the Board of ...

Germany's largest pharmaceutical company Boehringer Ingelheim on Wednesday reported a currency-adjusted 6.1% gain in 2024 revenues, buoyed by diabetes drug Jardiance and lung drug Ofev.

At the heart of the licensing deal is CUE-501, a bispecific molecule that can selectively deplete B cells to address autoimmune and inflammatory conditions.

A German pharmaceutical company is moving its U.S. animal health headquarters to a new Johns Creek project. Boehringer ...

Partnership bolsters Boehringer’s autoimmune and inflammatory disease pipeline portfolio aiming to tackle areas of high unmet patient ...